About Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Health Care Supplies
- Exchange: NASDAQ
- Symbol: CERS
- CUSIP: 15708510
- Previous Close: $4.28
- 50 Day Moving Average: $4.20
- 200 Day Moving Average: $5.29
- 52-Week Range: $103,466,000.00 - $3.97
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.12
- P/E Growth: 0.00
- Market Cap: $441.80M
- Outstanding Shares: 103,466,000
- Beta: 2.06
- Net Margins: -174.76%
- Return on Equity: -76.76%
- Return on Assets: -49.53%
Companies Related to Cerus Corporation:
- Debt-to-Equity Ratio: 0.20%
- Current Ratio: 4.72%
- Quick Ratio: 4.19%
What is Cerus Corporation's stock symbol?
Cerus Corporation trades on the NASDAQ under the ticker symbol "CERS."
Where is Cerus Corporation's stock going? Where will Cerus Corporation's stock price be in 2017?
4 brokers have issued 1-year price objectives for Cerus Corporation's shares. Their forecasts range from $8.00 to $10.00. On average, they anticipate Cerus Corporation's share price to reach $9.25 in the next year.
When will Cerus Corporation announce their earnings?
Cerus Corporation is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Cerus Corporation stock?
Cerus Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (1.73%), ARK Investment Management LLC (0.64%), Royce & Associates LP (0.24%), Baird Financial Group Inc. (0.20%), Trexquant Investment LP (0.10%) and A.R.T. Advisors LLC (0.09%). Company insiders that own Cerus Corporation stock include Kevin Dennis Green and Laurence M Corash.
Who sold Cerus Corporation stock? Who is selling Cerus Corporation stock?
Cerus Corporation's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY.
Who bought Cerus Corporation stock? Who is buying Cerus Corporation stock?
Cerus Corporation's stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Trexquant Investment LP, A.R.T. Advisors LLC, Renaissance Technologies LLC, J. Goldman & Co LP, Bayesian Capital Management LP, State Street Corp and Baird Financial Group Inc..
How do I buy Cerus Corporation stock?
Shares of Cerus Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cerus Corporation stock cost?
One share of Cerus Corporation stock can currently be purchased for approximately $4.27.